By activating GLP-1 receptors, Semaglutide enhances insulin secretion in response to meals, suppresses glucagon release (a hormone that raises blood sugar levels), and slows gastric emptying
GLP-1 receptor agonists, a class of drugs originally developed for type 2 diabetes and obesity that have recently transformed metabolic medicine, target the downstream consequences of that hormonal withdrawal: dysregulated energy metabolism, inflammation, and shifts in body composition
In multiple regression analysis, researchers found the results did not change when stratified by bariatric surgery type, adding that treatment group was the only significant predictor of percentage weight change
We are with you rep by rep, stride by stride, as you conquer your goals and redefine what's possible